

Table 1. Baseline Characteristics and Clinical Presentation in Survivors and Non-Survivors after DAH

Characteristics	Survivors (n=40)	Non Survivors (n=49)	P value
Age, years, median (range)	72 (20-100)	66 (23-95)	0.12
Males	25 (62)	30 (62)	0.9
Smoking status*	27 (67)	21 (42)	0.02
Active	6 (15)	5 (10)	
Former	21 (52)	16 (33)	
Never	13 (32)	20 (41)	
Hemoptysis	23 (57)	23 (48)	0.37
Dyspnea	39 (97)	48 (98)	0.9

Values provided as No. (%), unless otherwise indicated.

Abbreviations: DAH, Diffuse Alveolar Hemorrhage

*Smoking status was not available in 8 patients

Table 2. Causes of Diffuse Alveolar Hemorrhage

Cause	Survivors (n=40)	Non Survivors (n=49)
Malignancy	0 (0)	14 (28)
Infection	8 (20)	13 (26)
Interstitial lung disease	0 (0)	7 (14)
Coagulopathy	5 (12)	4 (8)
Drug-induced	0 (0)	3 (6)
Anticoagulant therapy	3 (7)	1 (2)
Autoimmune Disease	16 (40)	1 (2)
Thrombocytopenia	3 (7)	0 (0)
Congestive Heart Failure	2 (5)	1 (2)
Miscellaneous	3 (7)	5 (10)

Values provided as No. (%).

Table 3. Risk Factors for Diffuse Alveolar Hemorrhage

Variable	Survivors (n=40)	Non Survivors (n=49)	P value
Malignancy	7 (17)	24 (49)	0.002
Sepsis	16 (41)	22 (45)	0.7
Interstitial lung diseases	0 (0)	7 (14)	0.01
Idiopathic	3 (7)	4 (8)	0.8
Drug-induced	1 (2)	3 (6)	0.3
Anticoagulation	16 (41.03)	15 (30.61)	0.31
Congestive heart failure	10 (27)	9 (19.5)	0.4
Renal dysfunction	19 (47)	30 (61)	0.2
Liver failure	1 (2)	14 (28)	0.001
Connective tissue diseases	16 (40)	4(8)	0.0006
SLE	1 (2)	1 (2)	1
Mixed connective tissue disease	3 (7)	3 (6)	0.8
Microscopic polyangiitis	7 (18)	0 (0)	0.001
Granulomatosis with polyangiitis	2 (5)	0 (0)	0.1
Antiphospholipid syndrome	2 (5)	0 (0)	0.1
Dermatomyositis	1 (2)	0 (0)	0.3
Thrombocytopenia	3 (7)	35 (71)	<0.0001
Coagulopathy INR>1.5	15 (37)	22 (45)	0.5

Values provided as No. (%), unless otherwise indicated.

Abbreviations: Systemic Lupus Erythematosus; INR, International Normalized Ratio

Table 4. Management of Diffuse Alveolar Hemorrhage in Survivors and Non-Survivors

Variable	Survivors (n=40)	Non Survivors (n=49)	P value
ICU Admission, n (%)	23 (57)	40 (85)	0.004
ICU length of stay, days, mean ($\pm$ SD)	3.5 ($\pm$ 6.7)	5.5 ($\pm$ 5.5)	0.4
Duration of hospitalization, days mean ($\pm$ SD)	11 (($\pm$ 8.8)	10 (($\pm$ 9.3))	0.5
Antibiotics, n (%)	34 (85)	43 (90)	0.5
Steroids, n (%)	36 (90)	31 (63)	0.003
Immunosuppression, n (%)	6 (15)	9 (18)	0.7
Plasma Exchange, n (%)	6 (15)	0 (0)	0.005
ECMO, n (%)	0 (0)	1 (2)	0.3
ARDS, n (%)	9 (22)	37 (77)	<0.0001
Mechanical ventilation, n (%)	15 (37)	36 (75)	0.0007

Values provided as No. (%), unless otherwise indicated.

Abbreviations: ICU, Intensive Care Unit; ECMO, Extracorporeal Membrane Oxygenation; ARDS, Acute Respiratory Distress Syndrome

Table 5. Predictors of Mortality after DAH (adjusted for age and sex)

Variable	Odds Ratio (95% Confidence Interval)	p-value
Age		0.21
Sex		0.74
Thrombocytopenia	52.08 (8.59-315.71))	<.0001
ARDS	11.71 (2.60-52.67))	0.0013
Steroid Use	0.05 (0.007-0.39)	0.0004

Abbreviations: ARDS, Acute Respiratory Distress Syndrome; DAH, Diffuse Alveolar

Hemorrhage